



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Invega Trinza

Page: 1 of 1

Effective Date: 3/4/2024

Last Review Date: 01/2024

Applies to:	<input checked="" type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input checked="" type="checkbox"/> Florida Kids
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input checked="" type="checkbox"/> Kentucky PRMD

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Invega Trinza under the patient's prescription drug benefit.

### Description:

Invega Trinza (paliperidone palmitate), a 3-month injection, is indicated for the treatment of schizophrenia in patients after they have been adequately treated with Invega Sustenna (1-month paliperidone palmitate extended-release injectable suspension) for at least four months.

### Applicable Drug List

Formulary: Invega Trinza

### Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of schizophrenia
- AND**
- The patient has been adequately treated with Invega Sustenna for at least four months

### Approval Duration and Quantity Restrictions:

**Approval:** 12 months

**Quantity Level Limit:** Reference Formulary for drug specific quantity level limits

### References:

1. Invega Trinza [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2021.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, Ohio: UpToDate, Inc.; 2021; Accessed August 3, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com/>. Accessed August 3, 2021.
4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Third Edition. 2021. Available at: <https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841>. Accessed August 3, 2021.
5. McClellan J, Stock S, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013 Sep;52(9):976-90.